The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.
The purpose of Phase 2 Expansion Part B is to assess the objective response rate of HexaBody-CD38 versus subcutaneous daratumumab ... resulting in a proprietary pipeline including bispecific T-cell ...
GlobalData on MSN11d
Indonesia approves Antengene’s Xpovio NDA for multiple indicationsAntengene’s new drug application (NDA) for Xpovio (selinexor) has gained approval from the Indonesia National Agency of Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback